Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.58 USD -4.98%
Market Cap: 25.5m USD
Have any thoughts about
Pluri Inc?
Write Note

Pluri Inc
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pluri Inc
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Pluri Inc
NASDAQ:PLUR
Total Current Assets
$27m
CAGR 3-Years
-25%
CAGR 5-Years
5%
CAGR 10-Years
-6%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Total Current Assets
$28m
CAGR 3-Years
70%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Total Current Assets
$164.4m
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
5%
Urogen Pharma Ltd
NASDAQ:URGN
Total Current Assets
$295.1m
CAGR 3-Years
33%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Total Current Assets
$7.3m
CAGR 3-Years
-36%
CAGR 5-Years
3%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Total Current Assets
â‚Ş14.6m
CAGR 3-Years
-44%
CAGR 5-Years
55%
CAGR 10-Years
15%
No Stocks Found

Pluri Inc
Glance View

Market Cap
25.2m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
1.42 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Pluri Inc's Total Current Assets?
Total Current Assets
27m USD

Based on the financial report for Sep 30, 2024, Pluri Inc's Total Current Assets amounts to 27m USD.

What is Pluri Inc's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
-6%

Over the last year, the Total Current Assets growth was -23%. The average annual Total Current Assets growth rates for Pluri Inc have been -25% over the past three years , 5% over the past five years , and -6% over the past ten years .

Back to Top